hVIVOOPORF +27.29%43 Gross Margin % is 113.54% as of Dec. 2025, which is 18% above its 10-year median of 96.47. GuruFocus rates OPORF with a GF Score™ of 43/100 and a GF Value™ of $0.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, hVIVO ranks better than 58.46% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. hVIVO's Gross Profit for the
six
months ended in Dec. 2025 was $34.32 Mil. hVIVO's Revenue for the
six
months ended in Dec. 2025 was $30.23 Mil. Therefore, hVIVO's Gross Margin % for the quarter that ended in Dec. 2025 was 113.54%.
The historical rank and industry rank for hVIVO's Gross Margin % or its related term are showing as below:
OPORF'
s Gross Margin % Range Over the Past 10 Years
Min: 58.59 Med: 96.47 Max: 97.39
Current: 58.59
During the past 13 years, the highestGross Margin % of hVIVO was 97.39%. The lowest was 58.59%. And the median was 96.47%.
OPORF's Gross Margin % is ranked better than 58.46% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.97
vs OPORF: 58.59
hVIVO had a gross margin of 113.54% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for hVIVO was 0.00% per year.
hVIVO (OTCPK:OPORF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
hVIVO had a gross margin of 113.54% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
hVIVO Gross Margin % Related Terms
hVIVO Gross Margin % Historical Data
* Premium members only.
The historical data trend for hVIVO's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPORF vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, hVIVO's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
hVIVO Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, hVIVO's Gross Margin % distribution charts can be found below:
* The bar in red indicates where hVIVO's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
hVIVO (OPORF) has a Gross Margin % of 113.54% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on hVIVO and its competitors. This is 18% above median its historical median of 96.47. Over the past decade, hVIVO's Gross Margin % has ranged from 58.59 to 97.39. According to the industry distribution chart, hVIVO ranks #81 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 41.5%.
Is hVIVO's Gross Margin % too high?
hVIVO's current Gross Margin % of 113.54% is 18% above median its 10-year median of 96.47. Over the past 10 years, this metric has ranged from a low of 58.59 to a high of 97.39. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. hVIVO's value of 113.54% is 122.8% above this industry median. Based on the distribution chart, hVIVO ranks #81 out of 195 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, hVIVO has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does hVIVO's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, hVIVO ranks #81 out of 195 companies for Gross Margin %. This puts hVIVO in the upper half of its industry. The industry median Gross Margin % is 50.97. hVIVO's value of 113.54% is 122.8% above this benchmark. Historically, hVIVO's own Gross Margin % has ranged from 58.59 to 97.39 over the past decade. While the company's 10-year median is 96.47 vs. the industry median of 50.97, hVIVO has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. hVIVO's current Gross Margin % of 113.54% is 122.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on hVIVO and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. hVIVO's current Gross Margin % is 113.54%, which is 18% above median its own 10-year median of 96.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
Based on GuruFocus' analysis, hVIVO (OPORF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.11 — trading 81.7% below its estimated fair value. The current Gross Margin % is 113.54%, which is 18% above median its 10-year median of 96.47 and 122.8% above the Medical Diagnostics & Research industry median of 50.97. hVIVO's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For hVIVO (OPORF), the current Gross Margin % is 113.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is hVIVO (OPORF) Overvalued in 2026?
Based on GuruFocus' analysis, hVIVO stock appears to be undervalued.
The current stock price of $0.11 is trading 81.7% below its estimated GF Value™ of $0.60.
GuruFocus considers hVIVO to be Possible Value Trap.
Key valuation signals for OPORF:
Gross Margin %: 113.54% (18% above median its 10-year median of 96.47)
GF Value™: $0.60 vs. price of $0.11 (81.7% below fair value)
Industry Position: 122.8% above the Medical Diagnostics & Research median (#81 of 195)
No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
43GF Score
Get the complete analysis for OPORF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPORF has been successfully added to your 
